Portal de Periódicos da CAPES

WEEKLY MITOMYCIN C FOLLOWED BY MONTHLY BACILLUS CALMETTE-GUERIN OR ALTERNATING MONTHLY INTERFERON-α2B AND BACILLUS CALMETTE-GUERIN FOR PROPHYLAXIS OF RECURRENT PAPILLARY SUPERFICIAL BLADDER CARCINOMA

2000; Lippincott Williams & Wilkins; Volume: 164; Issue: 1 Linguagem: Inglês

10.1016/s0022-5347(05)67446-0

1527-3792

Eero Kaasinen, Erkki Rintala, A Père, Jukka Kallio, Veli‐Matti Puolakka, Tapani Liukkonen, Kari Tuhkanen,

Urologic and reproductive health conditions

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jul 2000WEEKLY MITOMYCIN C FOLLOWED BY MONTHLY BACILLUS CALMETTE-GUERIN OR ALTERNATING MONTHLY INTERFERON-α2B AND BACILLUS CALMETTE-GUERIN FOR PROPHYLAXIS OF RECURRENT PAPILLARY SUPERFICIAL BLADDER CARCINOMA EERO KAASINEN, ERKKI RINTALA, ANNA-KAISA PERE, JUKKA KALLIO, VELI-MATTI PUOLAKKA, TAPANI LIUKKONEN, KARI TUHKANEN, and THE FINNBLADDER GROUP* EERO KAASINENEERO KAASINEN , ERKKI RINTALAERKKI RINTALA , ANNA-KAISA PEREANNA-KAISA PERE , JUKKA KALLIOJUKKA KALLIO , VELI-MATTI PUOLAKKAVELI-MATTI PUOLAKKA , TAPANI LIUKKONENTAPANI LIUKKONEN , KARI TUHKANENKARI TUHKANEN , and THE FINNBLADDER GROUP* View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67446-0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated alternatives to bacillus Calmette-Guerin (BCG) monotherapy using a new combination of chemotherapy and immunotherapy for recurrent superficial bladder carcinoma. Materials and Methods: A total of 236 patients with frequently recurrent stage Ta or T1 bladder tumors were enrolled in our prospective, randomized, multicenter Finnbladder IV study. The initial mitomycin C instillation was instilled in all patients perioperatively after transurethral resection, followed by 4 weekly instillations of mitomycin C. Thereafter patients were randomized to receive monthly for up to 1 year BCG only or interferon-α2b and BCG alternating monthly. Primary end points were time to initial recurrence, recurrence rate (number of recurrences per patient-year) and recurrence index (number of recurrent tumors per patient-year). Results: Of the 236 randomized patients 205 were eligible for study with a median overall followup of 30.7 months. Monthly BCG was superior to alternating monthly interferon-α and/or BCG with respect to time to initial recurrence (log rank test p <0.00001) as well as recurrence rate (0.4 versus 0.9, p <0.00001) and index (0.9 versus 3.0, p <0.00001). Side effects were limited. Conclusions: Monthly BCG given for up to 1 year preceded by perioperative and an additional 4 weekly mitomycin C instillations is a well tolerated mode of instillation therapy, providing excellent tumor control comparable to that of the best reported instillation regimens. No benefit was obtained by alternating interferon-α2b with BCG. References 1 : Superficial bladder cancer: the role of interferon-α. J Urol1998; 159: 1793. Link, Google Scholar 2 : A randomized study of intravesical Mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol1995; 153: 929. Link, Google Scholar 3 : Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. Urology1998; 52: 403. Google Scholar 4 : BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol1995; 27: 2. Google Scholar 5 : The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol1997; 158: 62. Link, Google Scholar 6 : Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol1997; 80: 762. Google Scholar 7 : Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol1996; 156: 56. Link, Google Scholar 8 : Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J Urol1995; 154: 2050. Link, Google Scholar 9 : Tables of the number of patients required in clinical trials using the logrank test. Stat Med1982; 1: 121. Google Scholar 10 : 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol1999; 161: 1124. Link, Google Scholar 11 : A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Eng J Med1991; 325: 1205. Google Scholar 12 : Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol1998; 160: 1668. Link, Google Scholar 13 : Intravesical chemotherapy (MMC) versus immunotherapy (BCG) in superficial bladder cancer. Eur Urol1991; 20: 19. Google Scholar 14 : Significant long-term patient benefit with BCG maintenance therapy: a Southwest Oncology Group Study. J Urol1997; 157: 213. abstract 831. Google Scholar 15 : Towards the optimal BCG regimen: comparison of maintenance schedules. In: . Oxford: Medicine Group (Education.)1997: 103. Google Scholar 16 : Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer1995; 31A: 1840. Google Scholar 17 : Clinical characterization of risk profiles. In: . Oxford: Medicine Group (Education)1997: 25. Google Scholar 18 : Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol1988; 6: 476. Google Scholar 19 : Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer. Eur J Cancer1999; 35: 1123. Google Scholar 20 : A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Br J Urol1995; 76: 697. Google Scholar From the Hyvinkää Hospital, Hyvinkää, Helsinki City Hospital and Helsinki University Central Hospital, Helsinki, Tampere University Hospital, Tampere, South Karelian Central Hospital, Lappeenranta, Mikkeli Central Hospital, Mikkeli and Kuopio University Hospital, Kuopio, Finland© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 164Issue 1July 2000Page: 47-52 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordsinterferonsmitomycinmycobacterium bovisbladderpapillary carcinomaMetricsAuthor Information EERO KAASINEN More articles by this author ERKKI RINTALA More articles by this author ANNA-KAISA PERE More articles by this author JUKKA KALLIO More articles by this author VELI-MATTI PUOLAKKA More articles by this author TAPANI LIUKKONEN More articles by this author KARI TUHKANEN More articles by this author THE FINNBLADDER GROUP* More articles by this author Expand All Advertisement PDF DownloadLoading ...